- Research article
- Open Access
- Open Peer Review
Type 1 diabetes-associated cognitive impairment and diabetic peripheral neuropathy in Chinese adults: results from a prospective cross-sectional study
BMC Endocrine Disorders volume 19, Article number: 34 (2019)
To compare neurocognitive functioning of Type 1 diabetic mellitus (T1DM) and healthy adults, and explore risk factors of cognitive dysfunction of T1DM patients, especially the association between cognitive impairment and diabetic peripheral neuropathy (DPN).
Seventy T1DM (age: 32.17 ± 9.57 yr., duration: 8.99 ± 7.02 yr) patients and 48 healthy volunteers were included. All subjects received evaluation of MMSE and MoCA scales. Cognitive function of T1DM patients was evaluated in different cognitive domains. Risk factors affecting cognitive function were further explored.
Three patients with educational level ≤ 6-year were excluded from final analysis. Scores of both MMSE (28.4 ± 1.7 vs. 29.1 ± 1.0, P = 0.005) and MoCA scales (25.9 ± 2.7 vs.27.1 ± 2.4, P = 0.017) in T1DM group were lower than that in control group. For MMSE scale, scores of orientation (9.60 ± 0.79 vs.9.87 ± 0.39, P < 0.001) and language function (8.56 ± 0.65 vs.8.83 ± 0.38, P < 0.001) in T1DM groups were lower than that in control group. For MoCA scale, scores of attention and concentration (2.30 ± 0.74 vs.2.57 ± 0.58, P < 0.001), visuospatial/executive function (4.32 ± 0.91 vs.4.64 ± 0.63, P < 0.001), memory (2.96 ± 1.50 vs.3.66 ± 1.28, P < 0.001), language function (5.71 ± 0.69 vs.5.87 ± 0.39, P = 0.007), and abstraction (1.55 ± 0.68 vs.1.82 ± 0.42, P < 0.001) were lower in T1DM group than that in control group. Logistic regression showed age, fasting C peptide, educational level and nerve conduction velocity (NCV) were associated with cognitive dysfunction diagnosed by MoCA scores for the patients with type 1 diabetes.
T1DM adults had mild to moderate cognitive impairment, mainly presenting as dysfunctions of attention and concentration, visuospatial/executive, language, and abstraction. In addition to age, fasting C peptide level, and educational level, DPN, as a diabetic complication, was identified to be associated with cognitive impairments.
T1DM is a chronic autoimmune disease affecting multiple organs, which is characterized by total insulin deficiency essential for glucose metabolism. This in turn can lead to impairments in the brain and can affect cognitive function. People with T1DM have been shown to have mild to moderate cognitive impairment as measured by neuropsychological testing compared to non-diabetic controls . T1DM patients were reported to have cognitive dysfunction in different cognitive domains of varied degrees, ranging from general intellectual testing, to specific deficits with visuospatial abilities, motor speed, writing, attention, reading, and psychomotor efficiency [2, 3]. However, results have not always been consistent, regarding the extent and domains of cognitive difficulties and their associated risk factors.
Diabetic peripheral neuropathy (DPN) is also a common, debilitating, and distressing complication affecting up to 30–50% of patients with diabetes . DPN has only been considered as a disease of the peripheral nervous system in the past. Nevertheless, with advances in noninvasive magnetic resonance imaging (MRI), more and more evidences have shown central nervous system (CNS) involvement in DPN [5, 6]. Therefore it is speculated that cognitive impairment may be associated with DPN in T1DM.
In this study, we first compared the neurocognitive functioning of T1DM adults and healthy adults. In T1DM adults, we then examined the association between the cognitive function and multiple factors. We first confirmed that age, education and C peptide level are associated with the cognitive impairment in T1DM patients as previously reported [7, 8]. Next, using nerve conduction velocity (NCV) as an indicator of DPN, we investigated the relationship between cognitive impairment and occurrence of DPN in a Chinese population. Our findings thereby shed light on studies of effects of DPN on cognitive functions in T1DM patients.
We conducted a cross-sectional study of 118 adults (70 cases with T1DM and 48 healthy controls without chronic illness) older than 18-yr from the endocrine department and medical examination center at the Second Affiliated Hospital of Soochow University from Jan 2013 to Oct 2014. The diagnosis of type 1 diabetes mellitus was accorded with diagnostic criteria of WHO in 1999, made by endocrine specialists. T1DM patients fulfilled three criteria: duration of diabetes at least six months, right-handed, and stable glycemic control (HbA1c < 11%). Most patients in our study present in the classic way: rapid onset of hyperglycemia, weight loss, with marked symptoms. All patients have completed tests of pancreatic function, immune markers and islet autoantibodies before diagnosis of T1DM by more than 2 endocrine specialists and were treated using insulin with the guidance of endocrine specialists. Before enrollment, two endocrine and neuropsychological specialists confirmed that all subjects were confirmed that they were suitable for having neuropsychological assessments and no hospitalization within 3 months. HbA1c was done on the day of cognitive assessment. All subjects have been screened for potential causes of cognitive dysfunction. Before they were enrolled into the study, all of them were screened with routine blood test, electrolytes tests and thyroid function to exclude diseases that could potentially cause cognitive decline. In addition, we carefully reviewed all past medical records before we accepted subjects into this study. Exclusion criteria included: other neurological diseases, presence of nondiabetic neuropathies, history of long-term alcohol consumption, recurrent severe hypoglycemia, hypoglycemic unawareness, severe hepatic and renal dysfunction, incoordination for examination (severe anxiety or depression, mental retardation, language disorders). In the same period, demographically similar healthy controls who received a complete check of body health status at our health examination center, were consecutively enrolled. In the healthy examination center, as persons like, they can have biochemical examination of blood such as serum lipids, hepatic and renal function, and fasting glucose, also including tumor markers, thyroid function and so on by the same detecting instruments as T1DM patients. Additionally patients can have a CT or X- ray scan of any part of the body as indicated, even including MRI examinations. There are transcranial and carotid dopplers. Psychological assessments are included too. A matching ratio of 1:2 was used to enroll healthy controls and T1DM patients. Healthy controls were confirmed by normal fasting plasma glucose (FPG) and HbA1c levels, with matched age and educational levels to diabetic patients. For each healthy control included in the study, a standard diagnostic procedure was given including biochemical examinations of blood such as serum lipids, hepatic and renal function, glucose tests, tumor markers, and thyroid function as well as cranial CT scan and detailed history inquiry to exclude those with hypothyroidism, DM, tumor, hepatic and renal diseases, neurological illness, or peripheral neuropathy. More details were referenced to our previous publication . The study was approved by the local Ethics Committee of the Second Affiliated Hospital of Soochow University, and all patients or their family members signed informed consent forms.
Clinical variables and outcome evaluation
Detailed demographics information, including age, sex, duration, height, weight, educational levels, history of severe hypoglycemia, hyperglycemia, diabetic ketoacidosis (DKA) and family history of diabetes, was collected. HbA1c, FPG, blood lipids [total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL)], serum uric acid, serum C peptide, urine microalbumin, and urine creatinine of fasting blood and urine samples were analyzed.
Diagnosis of DPN
The diagnosis of DPN was made using ≥1 abnormal attribute in ≥2 separate nerves by NCV, adapted from the Toronto consensus. The cut off points for NCV measures are listed in the (Additional file 1: Tables S1-5). Briefly, if the conduction velocity is lower than − 20%, or amplitude is lower than lower limit, or latent period is longer than + 20%, or amplitude is lower than lower limit, the attribute is considered as abnormal. Bilateral comparison is also important. Significant differences between two sides means one side may be abnormal. One experienced specialist without knowledge of the history of subjects did the examinations in our study. We now included detailed protocol for NCV measure.
All patients received nerve conduction studies the same way described in our published article . In our previous study, CPT results showed left sural nerves were most easily injured . Therefore NCV of left sural nerves were used as a continual variable in the regression analysis of association between cognitive function and DPN.
Assessment of cognition
All participants (patients and controls) underwent assessment by Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA). MMSE is a 30-point questionnaire that is applied extensively in clinical and research settings to measure cognitive impairment. The test examines functions including registration (repeating named prompts), attention and calculation, recall, language, ability to follow simple commands and orientation . MoCA is a more elaborate test of a one-page 30-point test assessing several cognitive domains including memory recall, visuospatial abilities, attention and concentration, language, abstraction, calculation, and orientation . The interpretations of MMSE and MoCA scores may need to be corrected for educational attainment. 1 point should be added to the total score of MoCA if the person has less than or equal to 12-year education. Any score of MoCA scales greater than or equal to 26 points indicates a normal cognition . To avoid possible influences from particular time/status of the measurement, subjects were asked to complete tests in the morning (10:00 am) after breakfast without coffee and tea. Subjects sat in a quiet room with temperature 24 ± 1 °C, one to one interviewed. All subjects did not take other medicines except insulin. In all enrolled T1DM patients, four were diagnosed as stage I diabetic retinopathy (DR), two as stage II DR, both of which show no overt vision effects. To further confirm this, an ophthalmologist and a neuro-psychologist examined those patients and concluded there was no interference with visuo-spacial assessment for these 6 patients with DR. The evaluation was performed by a qualified neurologist who did not know about the histories of all participants. Before the assessment, all subjects received a fingertip blood glucose test to rule out hypoglycemia and hyperglycemia. The blood glucose levels ranged from 3.9 mmol/L to 10 mmol/L.
Results were expressed as a percentage, median with interquartile ranges, or mean ± SD. Differences in frequencies were compared with the Chi-square test. Comparisons of median values among groups were done by the Student t test, one-way ANOVA, or non-parametric tests, as appropriate. Type 1 patients were categorized into two groups according to the MoCA scores after corrected for educational attainment, a normal cognition group and an abnormal cognition group. Before we did the logistic regression, we examined the co-linearity of data by SPSS. We then applied the stepwise regression to avoid the co-linearity of data. We fitted a logistic model to estimate the association between cognitive function and several risk factors, especially NCV as a continual variable with OR (odds ratio) and 95%CI (confidence interval) after adjusting for potential confounders: sex (female = 0, male = 1), age, fasting glucose levels, serum uric acid concentrations, C peptide, creatinine ratio, HAb1C, educational attainment(no education = 0, ≤6-year education = 1, ~ ≤ 12-year education = 2, > 12-year education = 3),duration, and BMI.
All statistical analyses were 2-sided test. A P value< 0.05 was considered statistically significant. SPSS16.0 software (SPSS Inc., IBM, Chicago, IL, USA) was used for all analyses.
Diabetic and healthy control groups were not significantly different in mean age (P = 0.108), sex distribution (P = 0.934), and educational attainments (P = 0.446) (Table 1). The blood glucose levels ranged from 3.9 mmol/L to 10 mmol/L (mean ± SD: 6.5 ± 2.3 mmol/L) immediately before the cognitive assessment.
Cognitive function of type 1 patients compared with healthy controls
For educational level was associated with cognitive impairment and there were few patients in educational level ≤ 6-year education group, 3 patients in the group were excluded from the study. Table 2 shows scores from the cognitive assessments for T1DM patients and control subjects. The diabetic duration of T1DM patients is from 0.50 to 37 years, with mean 8.99 ± 7.02 years. The type 1 diabetes group scored lower on both the MMSE and MoCA compared with control subjects (28.4 ± 1.7 vs. 29.1 ± 1.0, P = 0.005; 25.9 ± 2.7 vs. 27.1 ± 2.4, P = 0.017, respectively). Based on the MoCA scores, there were 26 (38.2%) patients with cognitive impairment in T1DM group and 5 (10.6%) controls in healthy control group, with a significant difference between the two groups (P = 0.001).
Analysis of specific cognitive domains decline of T1DM patients compared with the healthy controls
For MMSE tests, scores on orientation and language of T1DM patient were significantly lower than those of healthy controls. For MoCA scales, scores on attention and concentration, memory, language, visuospatial and executive abilities, and abstraction of T1DM patients were significantly lower than those of healthy controls (Table 2).
The correlation between known risk factors and DPN and cognitive impairment of T1DM patients
T1DM patients were divided into two groups according to MoCA scores: impaired cognition group or normal cognition group. We then performed multiple logistic regression analysis. The first categorywas patients’ characteristics: age, gender, educational attainment, BMI, and diabetic duration. Among them, consistent with previous studies [3, 7], age and education showed correlations with cognitive impairment in T1DM patients. We then examined biochemical laboratory variables including fasting glucose, serum uric acid, C peptide, HbA1c, creatinine ratio, in which serum C peptide level was identified as a risk factor for cognitive impairment of T1DM patients. After confirming the accuracy of such logistic regression analysis, we calculated whether the NCV(m/s) showed a correlation with cognitive impairment in T1DM patients. Our results showed that abnormal NCV might be a risk factor for cognitive impairment in persons with Type 1 diabetes (Table 3).
It has been reported that T1DM patients have mild to moderate cognitive dysfunction compared to non-diabetic controls . The study provides data that will better characterize the impact of T1DM on adult cognitive functions. In addition, we revealed the association between cognitive dysfunction and DPN for the first time in a Chinese population. The results were consistent with the literatures about other races with some difference in affected cognitive domains [13, 14]. In our study, worse memory/language, visuospatial abilities and executive functions, abstraction, attention and concentration performance for T1DM adults were reported, which were basically consistent with previous results [3, 12]. Many of these functions depend on efficient information processing, which is the hallmark of cognitive problem in T1DM patients.
Our analysis revealed that DPN was positively associated with cognitive impairments in T1DM patients. Consistent with this, more and more evidences have been reported on central nervous system involvement for DPN patients [15, 16]. There have been further reports of CNS involvement in DPN including dysfunction of the somatosensory afferent pathways using evoked potentials, thalamic neuronal dysfunction, and perfusion abnormalities seen on MRI studies [17,18,19]. Selvarajah et al. identified reduced peripheral gray matter volume mainly localized to primary somatosensory cortex and supramarginal gyrus in subjects with established DPN, and greater thalamic gray matter volume reduction in subjects with painless DPN . Clinically relevant white matter hyperintensity (WMH) has been reported to play an important role in cognitive dysfunction and prevalent neuropathies in T1DM patients. Clinically relevant WMH were related to the slower information processing frequently observed in T1DM, and prevalent neuropathies tripled the odds for high WHM burden, independent of age or disease duration . All these data showed a connection between cognitive dysfunction and DPN in T1DM patients.
As complications of the same disease, there might be some similarities in the pathogenic mechanisms of both cognitive dysfunction and DPN. There are also several common risk factors for the development of both cognitive impairment and DPN. For example, the most important one is HAlb1c levels and chronic hyperglycemia state [12, 22]. Hyperglycemia could cause microvascular dysfunction in the blood-brain barrier, autoimmune injury of neurological tissue and alterations in the synthesis, availability, or reuptake of neurotransmitters, such as serotonin. It increases the production of oxygen free radicals and weaken the bodies’ antioxidant ability. Moreover, hyperglycemia inhibits specific Na+-dependent carrier and leads to decreased activity of Na+-K+-ATP enzyme, which results in slowing of nerve conduction velocity. Several studies have reported relationship between neuropsychological test performance and the presence of hyperglycemic complications like neuropathy [3, 23]. The incidence of neuropathy is also associated with some other risk factors, including a raised triglyceride level, body-mass index, smoking, and hypertension. The risk factors for cognitive impairment involve age of onset, and episodes of severe hypoglycemia. It is necessary to conduct clinical studies including all these risk factors to further explore the association between DPN and cognitive dysfunction. To dissect the common pathogenic mechanisms of both, further longitudinal clinical and morphological studies including T1DM patients with both cognitive and DPN are needed.
The current study has some limitations. We cannot determine causality because of the cross-sectional design. The sample size was relatively small. HbA1c levels were only determined once, so the relationship between continued blood sugar levels and cognitive dysfunction has not been discussed. There were seldom DKA or severe hypoglycemia attacks for the subjects, so we have not considered those factors into logistic analysis and the clinical significance of both hypo- and hyperglycemia on cognitive function could not be figured out. Therefore, it is cautioned that our findings should be supported by future work in larger prospective longitudinal studies.
In conclusion, this study has identified cognitive impairments in an adult Chinese population with T1DM and connection between cognitive dysfunction and DPN, which provides new insights on the pathogenic mechanisms of both cognitive impairment and DPN of T1DM patients. However, the definitive pathogenesis and alteration of cognitive impairment requires larger, prospective, longitudinal studies and appropriate, strict enrollment of subjects.
Body mass index
Central nervous system
Diabetic peripheral neuropathy
Fasting plasma glucose
Motor nerve conduction velocity
Mini-mental State Examination
Montreal Cognitive Assessment
Magnetic resonance imaging
Nerve conduction velocity
Sensory nerve conduction velocity
Type 1 diabetic mellitus
White matter hyperintensity
Moheet A, Mangia S, Seaquist ER. Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci. 2015;1353:60–71.
Ohmann S, Popow C, Rami B, Konig M, Blaas S, Fliri C, Schober E. Cognitive functions and glycemic control in children and adolescents with type 1 diabetes. Psychol Med. 2010;40:95–103.
Li W, Huang E, Gao S. Type 1 diabetes mellitus and cognitive impairments: a systematic review. J Alzheimers Dis. 2017;57:29–36.
Deli G, Bosnyak E, Pusch G, Komoly S, Feher G. Diabetic neuropathies: diagnosis and management. Neuroendocrinology. 2013;98:267–80.
Selvarajah D, Wilkinson ID, Davies J, Gandhi R, Tesfaye S. Central nervous system involvement in diabetic neuropathy. Cur Diab Rep. 2011;11:310–22.
Lee MC, Tracey I. Imaging pain: a potent means for investigating pain mechanisms in patients. Br J Anaesth. 2013;111:64–72.
Gubitosi-Klug RA. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care. 2014;37:44–9.
Zhou Y, Fang R, Liu LH, Chen SD, Tang HD. Clinical characteristics for the relationship between type-2 diabetes mellitus and cognitive impairment: a cross-sectional study. Aging Dis. 2015;6:236–44.
Zhang X, Fang C, Li X, Cao YJ, Zhang QL, Zhang HH, Huang Y, Hu J, Liu CF. Clinical characteristics and risk factors of diabetic peripheral neuropathy of type 1 diabetes mellitus patients. Diabetes Res Clin Pract. 2017;129:97–104.
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2015;53:695–9.
Tonoli C, Heyman E, Roelands B, Pattyn N, Buyse L, Piacentini MF, Berthoin S, Meeusen R. Type 1 diabetes-associated cognitive decline: a meta-analysis and update of the current literature. J Diabetes. 2014;6:499–513.
Nunley KA, Rosano C, Ryan CM, Jennings JR, Aizenstein HJ, Zgibor JC, Costacou T, Boudreau RM, Miller R, Orchard TJ, Saxton JA. Clinically relevant cognitive impairment in middle-aged adults with childhood-onset type 1 diabetes. Diabetes Care. 2015;38:1768–76.
Morys JM, Kozera GM, Neubauer-Geryk J, Kruszewski P, Wolnik B, Nyka WM, Bieniaszewski L. Statin use and cognitive impairment in patients with type 1 diabetes: an observational study. Clin Neuropharmacol. 2016;39:182–7.
Wilkinson ID, Selvarajah D, Greig M, Shillo P, Boland E, Gandhi R, Tesfaye S. Magnetic resonance imaging of the central nervous system in diabetic neuropathy. Curr Diab Rep. 2013;13:509–16.
Greig M, Tesfaye S, Selvarajah D, Wilkinson ID. Insights into the pathogenesis and treatment of painful diabetic neuropathy. Handb Clin Neurol. 2014;126:559–78.
Selvarajah D, Wilkinson ID, Emery CJ, Shaw PJ, Griffiths PD, Gandhi R, Tesfaye S. Thalamic neuronal dysfunction and chronic sensorimotor distal symmetrical polyneuropathy in patients with type 1 diabetes mellitus. Diabetologia. 2008;51:2088–92.
Selvarajah D, Wilkinson ID, Gandhi R, Griffiths PD, Tesfaye S. Microvascular perfusion abnormalities of the thalamus in painful but not painless diabetic polyneuropathy: a clue to the pathogenesis of pain in type 1 diabetes. Diabetes Care. 2011;34:718–20.
Northam EA, Rankins D, Lin A, Wellard RM, Pell GS, Finch SJ, Werther GA, Cameron FJ. Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care. 2009;32:445–50.
Selvarajah D, Wilkinson ID, Maxwell M, Davies J, Sankar A, Boland E, Gandhi R, Tracey I, Tesfaye S. Magnetic resonance neuroimaging study of brain structural differences in diabetic peripheral neuropathy. Diabetes Care. 2014;37:1681–8.
Nunley KA, Ryan CM, Orchard TJ, Aizenstein HJ, Jennings JR, Ryan J, Zgibor JC, Boudreau RM, Costacou T, Maynard JD, Miller RG, Rosano C. White matter hyperintensities in middle-aged adults with childhood-onset type 1 diabetes. Neurology. 2015;84:2062–9.
Zilliox LA, Chadrasekaran K, Kwan JY, Russell JW. Diabetes and cognitive impairment. Curr Diab Rep. 2016;16:87.
Ryan CM, Williams TM, Orchard TJ, Finegold DN. Psychomotor slowing is associated with distal symmetrical polyneuropathy in adults with diabetes mellitus. Diabetes. 1992;41:107–13.
We are deeply appreciative of the participants in this study and thank all staffs for their support and assiatance.
This study was supported by grants from the National Natural Science Foundation of China (81501291, 81471195, 81871193). This was also partly supported by the preponderant clinic discipline group project funding of the Second Affiliated Hospital of Soochow University (XKQ2015002). The funder of 81501291and 81871193 was Xin Ding who was the first author, analyzing and interpreting the patient data regarding the cognitive functioning and nerve conduction velocity(NCV) results, and writing part of the manuscript. The funder of 81471195 was Yong-Jun Cao who participated in the design of the study and monitoring its implement. The funder of XKQ2015002 was responsible for publication charges.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
This study was approved by the local Ethics Committee of the Second Affiliated Hospital of Soochow University, and the reference number was (2012)ethical review and scientific research no. k11. All patients or their family members signed informed consent forms to participate in the study. For the minor participants, a consent from their parents has been obtained.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ding, X., Fang, C., Li, X. et al. Type 1 diabetes-associated cognitive impairment and diabetic peripheral neuropathy in Chinese adults: results from a prospective cross-sectional study. BMC Endocr Disord 19, 34 (2019). https://doi.org/10.1186/s12902-019-0359-2
- Type 1 diabetes mellitus
- Cognitive function
- Diabetic periphery neuropathy
- C peptide